Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs

British Journal of Cancer

Volumn 103, Issue 9, 2010, Pages 1313-1317

  Cummings, J ^a   Raynaud, F ^b   Jones, L ^c   Sugar, R ^c   Dive, C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

biomarkers; clinical trials; fit for purpose; validation

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER;

ASSAY; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SHORT SURVEY; VALIDATION STUDY;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; TUMOR MARKERS, BIOLOGICAL; VALIDATION STUDIES AS TOPIC;

EID: 78049260524     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605910     Document Type: Short Survey

References (30)

1. Boulanger B, Chiap P, Dewe W, Crommen J, Hubert P (2003) An analysis of the SFSTP guide on validation of chromatographic bioanalytical methods: progress and limitations. J Pharm Biomed Anal 32: 753-765
2. Boulanger B, Rozet E, Moonen F, Rudaz S, Hubert P (2009) A risk-based analysis of the AAPS conference report on quantitative bioanalytical methods validation and implementation. J Chromatogr B Analyt Technol Biomed Life Sci 877: 2235-2243
3. Carden CP, Sarker D, Postel-Vinay S, Yap TA, Attard G, Banerji U, Garrett MD, Thomas GV, Workman P, Kaye SB, de Bono JS (2010) Can molecular biomarker-based patient selection in phase I trials accelerate anticancer drug development? Drug Discov Today 15: 88-97
4. Cummings J, Ranson M, Butt F, Moore D, Dive C (2007) Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma. Cancer Chemother Pharmacol 60: 921-924
5. Cummings J, Ward TH, Greystoke A, Ranson M, Dive C (2008) Biomarker method validation in anticancer drug development. Br J Pharmacol 153: 646-656
6. Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J, Morris S, Jowle D, Ward T, Cummings J, Dickinson G, Aarons L, Lacasse E, Robson L, Dive C, Ranson M (2009) Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol 27: 1660-1666
7. DeSilva B, Smith W, Weiner R, Kelley M, Smolec J, Lee B, Khan M, Tacey R, Hill H, Celniker A (2003) Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res 20: 1885-1900
8. Fast DM, Kelley M, Viswanathan CT, O'Shaughnessy J, King SP, Chaudhary A, Weiner R, DeStefano AJ, Tang D (2009) Workshop report and follow-up-AAPS Workshop on current topics in GLP bioanalysis: Assay reproducibility for incurred samples-implications of Crystal City recommendations. AAPS J 11: 238-241
9. Feinberg M (2007) Validation of analytical methods based on accuracy profiles. J Chromatogr A 1158: 174-183
10. Feinberg M, Boulanger B, Dewe W, Hubert P (2004) New advances in method validation and measurement uncertainty aimed at improving the quality of chemical data. Anal Bioanal Chem 380: 502-514
11. Findlay JW (2008) Specificity and accuracy data for ligand-binding assays for macromolecules should be interpreted with caution. AAPS J 10: 433-434
12. Findlay JW (2009) Some important considerations for validation of ligand-binding assays. J Chromatogr B Analyt Technol Biomed Life Sci 877: 2191-2197
13. Findlay JW, Smith WC, Lee JW, Nordblom GD, Das I, DeSilva BS, Khan MN, Bowsher RR (2000) Validation of immunoassays for bioanalysis: a pharmaceutical industry perspective. J Pharm Biomed Anal 21: 1249-1273
14. Greystoke A, Cummings J, Ward TH, Simpson K, Renehan A, Butt F, Moore D, Gietema J, Blackhall F, Ranson M, Hughes A, Dive C (2008) Optimisation of circulating biomarkers of cell death for routine clinical use. Ann Oncol 19: 990-995
15. Hou JM, Greystoke A, Lancashire L, Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A, Ranson M, Lorigan P, Dive C, Blackhall FH (2009) Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy. Am J Pathol 175: 808-816
16. Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6: 327-338
17. Kelley M, DeSilva B (2007) Key elements of bioanalytical method validation for macromolecules. AAPS J 9: E156-E163
18. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, Keller S, Weinryb I, Green M, Duan L, Rogers JA, Millham R, O'Brien PJ, Sailstad J, Khan M, Ray C, Wagner JA (2006) Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 23: 312-328
19. Lee JW, Figeys D, Vasilescu J (2007) Biomarker assay translation from discovery to clinical studies in cancer drug development: quantification of emerging protein biomarkers. Adv Cancer Res 96: 269-298
20. Lee JW, Weiner RS, Sailstad JM, Bowsher RR, Knuth DW, O'Brien PJ, Fourcroy JL, Dixit R, Pandite L, Pietrusko RG, Soares HD, Quarmby V,Vesterqvist OL, Potter DM, Witliff JL, Fritche HA, O'Leary T, Perlee L, Kadam S, Wagner JA (2005) Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res 22: 499-511
21. Ludwig JA, Weinstein JN (2005) Biomarkers in cancer staging, prognosis and treatment selection. Nat Cancer Rev 5: 845-856
22. Mahler HC, Friess W, Grauschopf U, Kiese S (2009) Protein aggregation: pathways, induction factors and analysis. J Pharm Sci 98: 2909-2934
23. McShane LM, Hunsberger S, Adjei AA (2009) Effective incorporation of biomarkers into phase II trials. Clin Cancer Res 15: 1898-1905
24. Nowatzke W, Wood E (2007) Best practices during bioanalytical method validation for the characterisation of assay reagents and the evaluation of analyte stability in assay standards, quality controls and study samples. AAPS J 9: E117-E122
25. Rozet E, Hubert C, Ceccato A, Dewe W, Ziemons E, Moonen F, Michail K, Wintersteiger R, Streel B, Boulanger B, Hubert P (2007) Using tolerance intervals in pre-study validation of analytical methods to predict in-study results. The fit-for-future-purpose concept. J Chromatogr A 1158: 126-137
26. Sarker D, Workman P (2007) Pharmacodynamic biomarkers for molecular cancer therapeutics. Adv Cancer Res 96: 213-268
27. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, Layloff T, Viswanathan CT, Cook CE, McDowall RD (1991) Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 16: 249-255
28. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A (2000) Bioanalytical method validation-a revisit with a decade of progress. Pharm Res 17: 1551-1557
29. Tan DS, Thomas GV, Garrett MD, Banerji U, de Bono JS, Kaye SB, Workman P (2009) Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development. Cancer J 15: 406-420
30. Viswanathan CT, Bansal S, Booth B, Destefano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG, Weiner R (2007) Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm Res 9: E30-E42